Feb 15th 2013 - Edison Investment Research today published a report on quickview entitled "Down, But Not Out". In summary, the report says:
Aveo has revealed final overall survival (OS) Phase III data for tivozanib in renal cell carcinoma (RCC), which shows a median OS of 28.8 months for tivozanib versus a median OS of 29.3 months with sorafenib in the control arm (p=0.105, HR=1.25). The OS trend in favour of the sorafenib arm is a clear concern with regard to tivozanib’s approvability by the FDA (PDUFA 28 July 2013), but the trial design may provide the mitigating circumstances to persuade the regulator that tivozanib has a role to play in RCC. A planned FDA advisory committee review of tivozanib in the coming months is therefore a major catalyst for the stock.
Edison, the investment intelligence firm, is the future of investor interaction with corporates. Our team of over 100 analysts and investment professionals work with leading companies, fund managers and investment banks worldwide to support their capital markets activity. We provide services to more than 400 retained corporate and investor clients from our offices in London, New York, Frankfurt, Sydney and Wellington. Edison is authorised and regulated by the Financial Conduct Authority (www.fsa.gov.uk/register/firmBasicDetails.do?sid=181584). more »